BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics


BeyondSpring, Inc. - Ordinary Shares (BYSI): $11.43

0.06 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BYSI Stock Price Chart Interactive Chart >

Price chart for BYSI

BYSI Price/Volume Stats

Current price $11.43 52-week high $21.50
Prev. close $11.37 52-week low $9.24
Day low $11.17 Volume 114,600
Day high $11.59 Avg. volume 234,486
50-day MA $10.39 Dividend yield N/A
200-day MA $12.39 Market Cap 447.39M

BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio


BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.


BYSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BYSI Latest Social Stream


Loading social stream, please wait...

View Full BYSI Social Stream

Latest BYSI News From Around the Web

Below are the latest news stories about BeyondSpring Inc that investors may wish to consider to help them evaluate BYSI as an investment opportunity.

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had non-inferior protection against CIN compared to pegfilgrastim (day 2 dose), while performing numerically better for reduction of febrile neutropenia and chemo dose delay, with significantly lower bone pain NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a gl

Yahoo | June 10, 2021

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting

Presentation data demonstrates that plinabulin, in combination with pegfilgrastim, not only improves CIN prevention but also reverses some of the immune suppressive profile of monotherapy pegfilgrastimNEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a late-breaking poster presentation of the company’s lead asset plinabulin, a

Yahoo | June 8, 2021

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the presentation of three abst

Yahoo | June 7, 2021

BeyondSpring (BYSI) Investor Presentation - Slideshow

The following slide deck was published by BeyondSpring Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | June 5, 2021

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapyFirst patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-small cell lung cancer (NSCLC) NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer thera

Yahoo | June 4, 2021

Read More 'BYSI' Stories Here

BYSI Price Returns

1-mo 20.06%
3-mo -10.84%
6-mo 1.15%
1-year -31.19%
3-year -57.68%
5-year N/A
YTD -6.31%
2020 -21.29%
2019 -17.33%
2018 -35.52%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7525 seconds.